Tinurilimab

Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system[1].

Product Specifications

CAS Number

[2226224-30-0]

Product Name Alternative

BAY 1834942

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tinurilimab.html

Purity

98.01

Solubility

H2O

Smiles

[Tinurilimab]

Molecular Weight

(144.76 kDa)

References & Citations

[1]Pinkert J, et al. T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction. Oncoimmunology. 2021 Dec 30;11 (1) :2008110.